COAs and DHTs – measure what matters
Technology solutions from early phase through to post-marketing.
ICON provides its full range of clinical, consulting and commercial services across several industry sectors.
Developing transformative therapies requires a flexible approach.
Partners making a difference.
A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.
ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
In this CNS whitepaper we examine how innovative methodologies and technologies are being implemented to improve the success rate of neurodegenerative clinical trials.
Approaching early phase trials strategically and anticipating obstacles can be critical to the later success of a therapeutic
What you need to know for compliant, efficient safety and efficacy monitoring
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
19 March 2025
25 March 2025
ICON Cares is our commitment to making a positive impact on our people, environment and our community.
Clinical Research. Evolved.
